MedWatch Bulletin For Physicians Under Consideration At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The report would be similar to CDC’s Morbidity & Mortality Weekly Report, Deputy Commissioner Gottlieb says.
You may also be interested in...
Drug Safety Bulletin Being Considered By FDA
The effort would be overseen by new Associate Center Director for Safety Policy & Communication Paul Seligman.
Drug Safety Bulletin Being Considered By FDA
The effort would be overseen by new Associate Center Director for Safety Policy & Communication Paul Seligman.
FDA "Drug Watch" Website To Include Three Categories Of Safety Information
The site will reflect information about serious adverse events, patient selection and monitoring, and risk minimization procedures, an FDA draft guidance states. Manufacturers will be notified "shortly before" information about a drug is first posted; agency suggests the site's information will not be used for promotional purposes.